Gene edting… editn… editing, time to fix our genome (1/3)

Over 6k genetic disorders are known. Only ~10% are “treatable”, and only four are curable. It is estimated that 1 in 50 people is affected by a known single-gene disorder.  Simple “text edits” in patients’ genomic information would be the holy grail for doctors and Biotechs. In this three-part series, we will unveil the world of gene editing and highlight the investment opportunities as it hits clinical trials.

Bottom line

The multi-Trillion-dollar genomic revolution may not be here yet, but we are getting very close to the multi-Billion-dollars foundation on which it will be based.

The last ten years have seen a flurry of sharp enough tools entering clinical trials: CRISPR, TALENs, zinc finger nucleases, base editing, prime editing, etc. As a result, cell therapy and in-vivo/in-situ gene editing are emerging as fields of interest for investors. 

Several roadblocks are still hindering the genetic medicine market from reaching its full potential but, at the same time, spurring technological innovation. Gene editing tools are newcomers, thus offering both hope and uncertainty. Discerning the most promising technologies is key to investors' performance.

This article is available to logged users.
Sign in or request a login.



This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.

As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.

The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.

Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.

It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.

Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.